Tiny study hopes to unlock why some melanoma patients respond to immunotherapy
NCT ID NCT03225365
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tracked immune cell changes in 5 people with advanced melanoma who were taking nivolumab with or without ipilimumab. Researchers took blood and skin samples at several time points to compare immune responses between those who responded to treatment and those who did not. The goal was to better understand why immunotherapy works for some patients but not others.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which patients will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong
This is a very small, observational study with only 5 participants, so results may not apply broadly. It does not test a new treatment, only measures immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Dermatologie, Centre Hospitalier Lyon Sud (HCL)
Pierre-Bénite, 69310, France